menu
    • menu
    [{"orgOrder":0,"company":"EpicentRx","sponsor":"Texas Children's Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RRx-001","moa":"Free radical (FRD)","graph1":"Oncology","graph2":"Phase I","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EpicentRx \/ Texas Children's Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"EpicentRx \/ Texas Children's Cancer Center"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RRx-001","moa":"||Free radical (FRD)","graph1":"Oncology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EpicentRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Undisclosed"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RRx-001","moa":"||Free radical (FRD)","graph1":"Oncology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EpicentRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Undisclosed"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RRx-001","moa":"||Free radical (FRD)","graph1":"Oncology","graph2":"Phase I","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EpicentRx \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"EpicentRx \/ Undisclosed"},{"orgOrder":0,"company":"EpicentRx","sponsor":"SciClone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RRx-001","moa":"Free radical (FRD)","graph1":"Oncology","graph2":"Phase III","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EpicentRx \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"EpicentRx \/ SciClone Pharmaceuticals"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RRx-001","moa":"Free radical (FRD)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EpicentRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Undisclosed"},{"orgOrder":0,"company":"EpicentRx","sponsor":"SciClone Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"RRx-001","moa":"Free radical (FRD)","graph1":"Oncology","graph2":"Phase III","graph3":"EpicentRx","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"EpicentRx \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"EpicentRx \/ SciClone Pharmaceuticals"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RRx-001","moa":"||Free radical (FRD)","graph1":"Oncology","graph2":"Phase III","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EpicentRx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EpicentRx \/ Undisclosed"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RRx-001","moa":"||Free radical (FRD)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EpicentRx \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RRx-001","moa":"||Free radical (FRD)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EpicentRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Undisclosed"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"RRx-001","moa":"Free radical (FRD)","graph1":"Neurology","graph2":"Preclinical","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EpicentRx \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"EpicentRx \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RRx-001","moa":"||Free radical (FRD)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EpicentRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Undisclosed"},{"orgOrder":0,"company":"EpicentRx","sponsor":"FightMND","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"RRx-001","moa":"Free radical (FRD)","graph1":"Neurology","graph2":"Preclinical","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EpicentRx \/ FightMND","highestDevelopmentStatusID":"4","companyTruncated":"EpicentRx \/ FightMND"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RRx-001","moa":"Free radical (FRD)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EpicentRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Undisclosed"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Texas Children\u2019s Hospital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"RRx-001","moa":"||Free radical (FRD)","graph1":"Oncology","graph2":"Phase I","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpicentRx \/ Texas Children\u2019s Hospital","highestDevelopmentStatusID":"6","companyTruncated":"EpicentRx \/ Texas Children\u2019s Hospital"}]

    Find Clinical Drug Pipeline Developments & Deals for RRx-001

    Menu

    RRx-001

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            EpicentRx

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            EpicentRx

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RRx-001

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer

                            Details : RRx-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Stomatitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 28, 2023

                            Lead Product(s) : RRx-001

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EpicentRx

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            EpicentRx

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RRx-001,Cisplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee Recogn...

                            Details : RRx-001 (nibrozetone) is a multifaceted small molecule inflammasome NLRP3/KEAP1 inhibitor with tumor-targeted cytotoxicity and healthy tissue cytoprotective properties, which is investigated for the treatment of small cell lung cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 06, 2023

                            Lead Product(s) : RRx-001,Cisplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            EpicentRx

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            EpicentRx

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RRx-001

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EpicentRx Receives Fast Track Designation from the U.S. FDA for Lead Asset, RRx-001, to Prevent/Attenuate Chem...

                            Details : RRx-001 is a highly selective NLRP3 inhibitor with vascular normalization and tumor associated macrophage polarization properties that resensitizes tumors to previously administered therapies. It is under investigation SCLC, head and neck cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 29, 2023

                            Lead Product(s) : RRx-001

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            EpicentRx

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            EpicentRx

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RRx-001,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Promising Safety and Efficacy Signals from a Small Phase 1 Pilot Study (PRIMETIME) with RRx-001 + Opdivo® [ni...

                            Details : RRx-001 plus opdivo (nivolumab) as a combinaton is being investigated for advanced checkpoint inhibitor non-responsive tumors, where RRx-001 is a highly selective NLRP3 inhibitor and nivolumab monoclonal antibody that targets the anti-PD1 receptor.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 15, 2023

                            Lead Product(s) : RRx-001,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            EpicentRx

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            EpicentRx

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RRx-001,Bevacizumab,Irinotecan HCl Trihydrate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EpicentRx Announces Presentation for Phase 2 Randomized, Active-controlled, Multicenter Trial to Assess the Sa...

                            Details : RRx-001 is a highly selective NLRP3 inhibitor with vascular normalization and tumor associated macrophage polarization properties that resensitizes tumors. RRx-001 is under investigation for SCLC and for protection against oral mucositis in first line he...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 20, 2023

                            Lead Product(s) : RRx-001,Bevacizumab,Irinotecan HCl Trihydrate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            EpicentRx

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            EpicentRx

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RRx-001,Cisplatin

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EpicentRx Publishes Phase 2 Results for RRx-001 as an Anti-Mucositis Agent in Patients Receiving Radiation for...

                            Details : RRx-001 is a highly selective NLRP3 inhibitor with vascular normalization and tumor associated macrophage polarization properties that resensitizes tumors to previously administered therapies. It is under investigation SCLC, head and neck cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 19, 2023

                            Lead Product(s) : RRx-001,Cisplatin

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            EpicentRx

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            EpicentRx

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RRx-001,Bevacizumab,Regorafenib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RRx-001 + Irinotecan Significantly Improved Progression Free Survival (PFS) Versus Regorafenib in the Randomiz...

                            Details : RRx-001 is a highly selective NLRP3 inhibitor with vascular normalization and tumor associated macrophage polarization properties that resensitizes tumors to previously administered therapies.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 14, 2022

                            Lead Product(s) : RRx-001,Bevacizumab,Regorafenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            EpicentRx

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            EpicentRx

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RRx-001,Cisplatin

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EpicentRx Announces Patent Issued for Radiation Protection with RRx-001 in Combination Regimens

                            Details : The potential of RRx-001 as a radiation protection agent is related to evidence of NLRP3 inflammasome inhibition and Nrf2 activation, reducing the toxicity of radiation through the suppression of inflammation, free radical and oxidative stress.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 06, 2022

                            Lead Product(s) : RRx-001,Cisplatin

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            EpicentRx

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            EpicentRx

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RRx-001

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : FightMND

                            Deal Size : $0.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            EpicentRx Awarded Funding from FightMND to Evaluate Therapeutic Potential of RRx-001 in Motor Neuron Disease (...

                            Details : FightMND to evaluate the potential neuroprotective benefits of the company's lead small molecule, RRx-001. RRx-001, a direct NLRP3 inflammasome inhibitor, will be evaluated as a novel disease modifying therapy for MND.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 29, 2022

                            Lead Product(s) : RRx-001

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : FightMND

                            Deal Size : $0.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            EpicentRx

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            EpicentRx

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RRx-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : SciClone Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Do...

                            Details : RRx-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Small Cell Lung Carcinoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 04, 2022

                            Lead Product(s) : RRx-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : SciClone Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth